Prostate-Specific Membrane Antigen–Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas

Roberto Andres Salas Fragomeni, Joshua R. Menke, Matthias Holdhoff, Clare Ferrigno, John Joseph Laterra, Lilja B. Solnes, Mehrbod S. Javadi, Zsolt Szabo, Martin G. Pomper, Steven P. Rowe

Research output: Contribution to journalArticle

Abstract

ABSTRACT: High-grade gliomas (World Health Organization grade III–IV) are highly lethal primary brain tumors. Imaging modalities, including MRI and FDG PET, provide a limited ability to differentiate treatment effects (such as radiation necrosis) from recurrent or residual tumor. As the first step in validating the applicability of prostate-specific membrane antigen (PSMA)–targeted imaging in high-grade gliomas, we evaluated the ability of the PSMA-targeted small molecule [F]DCFPyL (2-(3-(1carboxy-5-(6-[F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid) to image high-grade gliomas in a series of 3 prospectively recruited patients. We found [F]DCFPyL binds PSMA in the neovasculature of glioblastoma multiforme and tumor cells of anaplastic astrocytoma.

Original languageEnglish (US)
JournalClinical Nuclear Medicine
DOIs
StateAccepted/In press - Jul 22 2017

Fingerprint

Prostate-Specific Antigen
Glioma
Membranes
Astrocytoma
Residual Neoplasm
Glioblastoma
Brain Neoplasms
Necrosis
Radiation
Acids
Neoplasms

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

@article{127b959a6e864f8388f2658ea5c8276e,
title = "Prostate-Specific Membrane Antigen–Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas",
abstract = "ABSTRACT: High-grade gliomas (World Health Organization grade III–IV) are highly lethal primary brain tumors. Imaging modalities, including MRI and FDG PET, provide a limited ability to differentiate treatment effects (such as radiation necrosis) from recurrent or residual tumor. As the first step in validating the applicability of prostate-specific membrane antigen (PSMA)–targeted imaging in high-grade gliomas, we evaluated the ability of the PSMA-targeted small molecule [F]DCFPyL (2-(3-(1carboxy-5-(6-[F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid) to image high-grade gliomas in a series of 3 prospectively recruited patients. We found [F]DCFPyL binds PSMA in the neovasculature of glioblastoma multiforme and tumor cells of anaplastic astrocytoma.",
author = "{Salas Fragomeni}, {Roberto Andres} and Menke, {Joshua R.} and Matthias Holdhoff and Clare Ferrigno and Laterra, {John Joseph} and Solnes, {Lilja B.} and Javadi, {Mehrbod S.} and Zsolt Szabo and Pomper, {Martin G.} and Rowe, {Steven P.}",
year = "2017",
month = "7",
doi = "10.1097/RLU.0000000000001769",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Prostate-Specific Membrane Antigen–Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas

AU - Salas Fragomeni,Roberto Andres

AU - Menke,Joshua R.

AU - Holdhoff,Matthias

AU - Ferrigno,Clare

AU - Laterra,John Joseph

AU - Solnes,Lilja B.

AU - Javadi,Mehrbod S.

AU - Szabo,Zsolt

AU - Pomper,Martin G.

AU - Rowe,Steven P.

PY - 2017/7/22

Y1 - 2017/7/22

N2 - ABSTRACT: High-grade gliomas (World Health Organization grade III–IV) are highly lethal primary brain tumors. Imaging modalities, including MRI and FDG PET, provide a limited ability to differentiate treatment effects (such as radiation necrosis) from recurrent or residual tumor. As the first step in validating the applicability of prostate-specific membrane antigen (PSMA)–targeted imaging in high-grade gliomas, we evaluated the ability of the PSMA-targeted small molecule [F]DCFPyL (2-(3-(1carboxy-5-(6-[F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid) to image high-grade gliomas in a series of 3 prospectively recruited patients. We found [F]DCFPyL binds PSMA in the neovasculature of glioblastoma multiforme and tumor cells of anaplastic astrocytoma.

AB - ABSTRACT: High-grade gliomas (World Health Organization grade III–IV) are highly lethal primary brain tumors. Imaging modalities, including MRI and FDG PET, provide a limited ability to differentiate treatment effects (such as radiation necrosis) from recurrent or residual tumor. As the first step in validating the applicability of prostate-specific membrane antigen (PSMA)–targeted imaging in high-grade gliomas, we evaluated the ability of the PSMA-targeted small molecule [F]DCFPyL (2-(3-(1carboxy-5-(6-[F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid) to image high-grade gliomas in a series of 3 prospectively recruited patients. We found [F]DCFPyL binds PSMA in the neovasculature of glioblastoma multiforme and tumor cells of anaplastic astrocytoma.

UR - http://www.scopus.com/inward/record.url?scp=85025693590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025693590&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000001769

DO - 10.1097/RLU.0000000000001769

M3 - Article

JO - Clinical Nuclear Medicine

T2 - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

ER -